Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Study of Mirabegron in Japanese Patients with Overactive Bladder
NCT00840645Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirabegron in overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoint: Vital signs, Adverse Events, laboratory tests, ECG, post-void residual volume at 52 weeks. Started Dec 2008; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00840645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00840645.